A Playbook for Emerging Biotechs

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

whitePaper | July 17, 2023

As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.